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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a growing economic burden worldwide. Smoking cessation
is thought to be the single most effective way of reducing the economic burden of COPD. The impact of other strategies
such as interventions that predict risk of disease, reduce progression of disease, or reduce exacerbations has not been
systematically studied.
Objectives: We estimated the economic and clinical burden of COPD over the next 25 years in Canada and the impact of
three potential interventions (screening test for predisposition to COPD, new drugs to avoid progression into more severe
disease stages, and predictive test for exacerbations) on COPD burden.
Methods: Using a dynamic simulation model, we projected the total burden of COPD (cost, morbidity, and mortality) from
2011 to 2035 using the population of Canada as a case study. The model stratified population based on sex, age, smoking
status, respiratory symptoms, and their COPD stage. The cost and quality adjusted life years (QALYs) associated with each
intervention were estimated.
Results: The model indicates that annual societal cost of COPD is $4.52 billion (B) Canadian dollars in 2011 and will reach
$3.61B ($7.33B undiscounted) per year in 2035. Over the next 25 years, COPD will be responsible for approximately $101.4B
in societal costs ($147.5B undiscounted) and 12.9 million QALYs lost (19.0 million undiscounted). Our results suggested that
the best strategy to reduce the financial burden of COPD is by reducing exacerbations. Smoking cessation, while it is the
cornerstone of COPD prevention, has only a modest effect in attenuating the financial burden of COPD over the next 25
years in Western countries such as Canada.
Conclusion: Our data suggest that any intervention that can reduce the number of exacerbations has a substantial impact
on morbidity and costs of COPD and should be considered in conjunction with the ongoing efforts to reduce smoking rates.
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Introduction
The human and economic burden of chronic obstructive
pulmonary disease (COPD) is substantial and is rapidly increasing
worldwide [1]. COPD is now the fourth leading cause of mortality
globally [2] and the third leading cause in the US [3]. Given the
enormous burden of COPD across the world, there is significant
interest in developing population-based programs to address this
global crisis. It is widely believed that smoking cessation is the
single most effective intervention for COPD [4]. However, the
impact of other strategies such as those that control progression, or
reduce exacerbations has not been systematically evaluated. In
particular, new discoveries about molecular biomarkers that can
provide information about predisposition, diagnosis, and prognosis
of COPD have raised the possibility of utilizing these potential
biomarkers to reduce burden of COPD [5–7]. Although clinical
usefulness of these biomarkers remains to be validated, better
understanding about their potential impact on COPD is valuable.
For instance, by comparing the long term clinical and economic
outcomes of using these molecular tests, we can rank strategies
based on their potential benefit at the population level.
In the current study, we evaluated the impact of three potential
interventions that targeted different stages of the disease using
hypothetical molecular tests. For this purpose, we first developed a
dynamic model that projected the total burden of COPD
(epidemiology, cost, morbidity, and mortality) over the next 25
years using the population of Canada as a case study. Then, by
PLOS ONE | www.plosone.org 1 October 2012 | Volume 7 | Issue 10 | e46746measuring the clinical and economic outcomes, we estimated the
incremental cost and incremental effectiveness of using each
potential intervention and compared the results across the three
interventions. Finally, we discuss the implications of our findings
for prioritization of interventions to reduce the global burden of
COPD.
Methods
1. Structure of the model
Based on data from the existing literature and population
growth projections from Statistics Canada [8], the present study
built a system-wide dynamic simulation model using VensimH
PLE Plus Version 5.10e (Harvard, MA, USA) to predict the future
burden of COPD (Figure 1). The dynamic model used
demographics data, which took into account projected annual
rates of birth, immigration, emigration, and mortality from 2011
to 2035, of Canadians 40 years or older (40–49, 50–59, 60–69,
$70 years)[8]. The Canadian population for each age group was
further divided into based on sex (men, women), smoking status
(current smokers, previous smokers, and non smokers), presence of
respiratory symptoms (symptomatic vs. asymptomatic), and
COPD severity stage (no COPD, mild, moderate, or severe).
The prevalence estimates for each disease severity of COPD
were based on data from the BOLD study [9], which ascertained
estimates of COPD in the general population of individuals 40
years and older using post-bronchodilator spirometry. Since many
subjects in the BOLD who demonstrated significant airflow
limitation (i.e. COPD) had never been diagnosed clinically with
COPD, these estimates included both diagnosed and undiagnosed
COPD. We followed the Global initiative for chronic Obstructive
Lung Disease (GOLD) classification scheme (in accordance with
BOLD study) to divide COPD patients into three levels of disease
severity: mild (GOLD I), moderate (GOLD II), and severe (GOLD
III or IV).
Spirometry is the currently accepted method for diagnosing
COPD and determining disease severity (based on patients’ forced
expiratory volume in one second (FEV1) values). However, in
practice, spirometry is not always used to make the diagnosis. In
these cases, diagnosis is based on clinical judgement. Thus, we
assumed that only a percentage of symptomatic individuals would
undergo spirometry testing. Given the actual prevalence of COPD
in each sub-group (based on BOLD study) and the performance
characteristics of spirometry (i.e., sensitivity and specificity), the
model estimated sub-groups with a true positive (TP), false
negative (FN), false positive (FP), and true negative (TN) diagnosis
of COPD based on spirometry results. The sub-group with
undiagnosed COPD (UD) was also included in the model. This
sub-group (i.e. UD) consisted of mild asymptomatic COPD
Figure 1. Model structure. Footnotes: i: 40–49, 50–59, 60–69, 70+. j: Current Smoker, Previous Smoker, Never Smoker. t: Time. UD: Undiagnosed;
TP: True Positive; TN: True Negative; FP: False Positive; FN: False Negative. The model ran separately for men and women.
doi:10.1371/journal.pone.0046746.g001
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undergo spirometry.
All TP, FN, and UD patients were initially classified as mild
COPD; however, UD and FN cases were assumed to be correctly
diagnosed (TP) if they progressed into the moderate or severe
stages of disease (i.e., there were no FN or UD patients with
moderate or severe COPD as symptoms would lead to a diagnosis
of COPD). Progression rates across the different stages of the
disease (mild, moderate, and severe) were calculated based on
changes in lung function related to aging and smoking status [10]
(Table 1). Individuals were able to move between different sub-
groups in the model (e.g. moving from younger age group to the
next age group, or moving from current smoker to previous
smoker subgroups) depending on the natural pathways and
potential interventions defined in the model. The effect of smoking
cessation was modeled as transition from the current sub-group
into previous smoker sub-group. Therefore, subsequent disease
trajectories were modified according to parameters that corre-
sponded to previous smokers.
2. Model Assumptions
A. Input Parameters. There is significant variability in the
estimated prevalence of COPD across various studies owing in
large part to the use of different case definitions. For this analysis,
we used the GOLD criteria for diagnosis [11]. Based on this
definition, the prevalence of mild, moderate, and severe COPD is
reported to be 11.1% (SE 1.2), 7.3% (SE 1.0), and 0.9% (SE 0.3) in
adults 40 years of age or older, respectively in the sample of the
population in Vancouver, Canada [9]. We considered these
estimates to be representative of rates across Canada [12]. We
used sub-group specific prevalence rates in the model in order to
account for differences in COPD prevalence related to age, sex,
smoking status, and COPD severity stage (Table 1). The sub-
group specific incidence rates of mild COPD were then calculated
based on the sub-group specific prevalence rates and changes in
the size (i.e. number of individuals) in each sub-group. Therefore,
the incidence of mild COPD in each sub-group was proportional
to the changes in the population in that sub-group (i.e. sub-group
specific prevalence rates of mild COPD did not change by time).
Incidence rates of moderate and severe COPD in each sub-group
were then determined in the model based on the transition rates
from mild to moderate and from moderate to severe stages
(Table 1).
Exacerbations are major drivers of COPD morbidity and
mortality. We modeled the likelihood of exacerbations according
to disease severity (Table 2). The annual rates of minor (defined as
an increase in symptoms requiring office visits and treatment with
oral corticosteroids or antibiotics) and major exacerbations
(defined as an increase in symptoms requiring an emergency visit
or hospitalization) in each sub-group were projected based on
published exacerbation rates and the number of COPD cases at
any given time with a specific level of disease severity [13,14].
B. Mortality. The background mortality rates were assumed
to be related to age and smoking status. The mortality rate from
COPD is estimated to be 10,000 deaths per year in Canada (30.4
per 100,000 persons)[12]. In the model, it was assumed that any
COPD related death was associated with a major exacerbation. As
such, the impact of smoking status, age, and disease severity on
COPD-related mortality was captured indirectly by their effect on
exacerbations (Table 1).
C. Quality of life. The model captured COPD related
morbidity by using quality adjusted life years (QALYs). We
assumed that COPD had a negative impact on patients’ quality of
life and that it was proportional to disease severity (Table 1). We
also assumed that exacerbations reduced quality of life for the
patient. The impact of COPD on patients’ quality of life was
captured using the EQ-5D utility weights [15,16]. Age specific
EQ-5D utility weights derived from the general Canadian
population [17] were used as reference utility weights to measure
the area under the curve of QALYs lost due to COPD. Deaths
were converted to equivalent QALY losses by assuming that the
quality of life of patients dropped to zero at the time of death. The
model calculated the overall QALYs lost at the population level,
incorporating the number of COPD deaths, the number of COPD
cases (mild, moderate, and severe), and the number of minor/
major exacerbations over time (Table 1). We assumed that the
quality of life of UD and FN patients was affected by COPD
(similar to a TP patient).
D. Costs. The direct annual cost of COPD and exacerbations
were modeled differentially based on COPD disease severity.
Using previously derived data [13], we modeled the direct costs of
maintenance therapy for the projected number of patients at each
stage of the disease. Direct costs of exacerbations were also
calculated based on the estimated unit cost per minor/major
exacerbations [13] (Table 1) and the frequency of exacerbation
episodes throughout the simulation. We assumed that patients
with mild COPD who were undiagnosed (UD) or misdiagnosed
(FN) did not generate any maintenance costs, while all TP and FP
cases were assumed to accrue maintenance costs (e.g. costs related
to drug treatment). However, we assumed that all COPD patients,
including UD and FN cases, were at risk of experiencing an
exacerbation and we incorporated associated costs with exacer-
bation for those cases [18,19]. We also considered indirect costs
related to COPD, which accounts for approximately 20%, 33%,
and 45% of total costs for mild, moderate, and severe COPD
patients respectively. [20] (Table 1)
E. Model perspective. The time horizon of the simulation
was from 2011 to 2035. We populated the model to simulate the
burden of COPD in Canada, and as such, Canadian unit costs
were used to estimate the economic burden of COPD. However,
exchange rates between Canadian and US dollar have also been
reported to facilitate some basic comparisons. The costs and
QALYs were discounted at 3% annual discount rate in the base
case scenario. However, the effects of other discount rates were
also captured in the sensitivity analysis. The unit costs reported in
earlier studies [13] were adjusted using Consumer Price Index
(CPI) in Canada to approximate 2011 unit costs.
3. Model validation and sensitivity analysis
The model was initially calibrated to replicate observed
population trends as predicted by Statistics Canada [8]. The
structure of the model and input parameters was carefully
discussed with expert clinicians and the model was validated by
comparing the predicted epidemiological variables against the
predictions in a number of independent studies. Furthermore, the
results were examined under several extreme scenarios to assure
robustness and internal validity of the model. Extensive one way
sensitivity analyses were conducted to evaluate the effect of
variation in input parameters on the results. Since long-standing
asthma may be a risk factor for COPD, we also modeled the
possible impact of the rising rates of asthma on the costs of COPD
over time.
4. Modeling of interventions
We estimated the outcomes for the following three hypothetical
interventions.
Economic Burden of COPD
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No COPD Mild Moderate Severe Reference
Background annual mortality rates (per 10,000) Estimated
a, Appendix S2
Men
Current smokers
40–49 27.0 27.0 27.0 27.0
50–59 69.0 69.0 69.0 69.0
60–69 186.0 186.0 186.0 186.0
70+ 830.7 830.7 830.7 830.7
previous smokers
40–49 18.9 18.9 18.9 18.9
50–59 48.3 48.3 48.3 48.3
60–69 130.2 130.2 130.2 130.2
70+ 581.5 581.5 581.5 581.5
Never smokers
40–49 16.2 16.2 16.2 16.2
50–59 41.4 41.4 41.4 41.4
60–69 111.6 111.6 111.6 111.6
70+ 498.4 498.4 498.4 498.4
Women
Current smokers
40–49 16.8 16.8 16.8 16.8
50–59 43.0 43.0 43.0 43.0
60–69 108.9 108.9 108.9 108.9
70+ 694.8 694.8 694.8 694.8
Previous smokers
40–49 11.8 11.8 11.8 11.8
50–59 30.1 30.1 30.1 30.1
60–69 76.2 76.2 76.2 76.2
70+ 486.4 486.4 486.4 486.4
Never smokers
40–49 10.1 10.1 10.1 10.1
50–59 25.8 25.8 25.8 25.8
60–69 65.3 65.3 65.3 65.3
70+ 416.9 416.9 416.9 416.9
Prevalence of respiratory symptoms (%) Estimated using Mannino et
al [36]
b, Appendix S2
Men
Current Smokers 36.7 95.1 95.1 95.1
Previous smokers 19 49.2 49.2 49.2
Never smokers 14.5 37.6 37.6 37.6
Women
Current Smokers 40 100 100 100
Previous smokers 24.7 64.1 64.1 64.1
Never smokers 21.8 56.5 56.5 56.5
Spirometry test uptake rate 37% - - - Camp et al [12]
Sensitivity of spirometry test 92% - - - Schneider et al [37]
Specificity of spirometry test 84% - - - Schneider et al [37]
Distribution of COPD stages in Men (%) Estimated
c, Appendix S2
Current smokers
40–49 79.3 17.0 3.4 0.4
50–59 74.4 17.0 7.7 0.8
Economic Burden of COPD
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No COPD Mild Moderate Severe Reference
60–69 67.0 17.0 14.5 1.6
70+ 48.0 17.0 31.6 3.4
Previous smokers
40–49 81.4 15.2 3.0 0.3
50–59 77.1 15.2 6.9 0.7
60–69 70.4 15.2 13.0 1.4
70+ 53.4 15.2 28.3 3.0
Never smokers
40–49 89.6 8.5 1.7 0.2
50–59 87.2 8.5 3.9 0.4
60–69 83.5 8.5 7.2 0.8
70+ 74.0 8.5 15.8 1.7
Distribution of COPD stages in Women (%) Estimated
c, Appendix S2
Current Smokers
40–49 72.3 24.4 2.5 0.8
50–59 72.3 24.4 2.5 0.8
60–69 47.9 24.4 20.9 6.8
70+ 22.5 24.4 40.0 13.1
Previous Smokers
40–49 90.7 8.2 0.8 0.3
50–59 90.7 8.2 0.8 0.3
60–69 82.5 8.2 7.0 2.3
70+ 73.9 8.2 13.5 4.4
Never Smokers
40–49 91.9 7.1 0.7 0.2
50–59 91.9 7.1 0.7 0.2
60–69 84.9 7.1 6.1 2.0
70+ 77.5 7.1 11.6 3.8
Exacerbation rates (per patient year) - 0.79 1.22 1.47 Spencer et al [13]
Proportion of minor exacerbations (%) - 94 93 90 Spencer et al [13]
Proportion of major exacerbations (%) - 6 7 10 Spencer et al [13]
Probability of death per major exacerbation (%) - 4.6 4.6 4.6 Estimated using Camp et al
[12]
d
Average progression time into the next COPD stage (years), Men Estimated
e, Appendix S2
Current smokers - 22 16 -
Previous smokers - 30 21 -
Never smokers - 30 21 -
Average progression time into the next COPD stage (years), Women Estimated
e, Appendix S2
Current smokers - 22 17 -
Previous smokers - 32 21 -
Never smokers - 32 21 -
Utilities
f
40–49 0.874 Johnson et al [17]
50–59 0.864
60–69 0.828
70–79 0.79
Chronic stage (all ages) 0.81 0.72 0.67 Spencer et al [13]
Minor exacerbation (all ages) 0.72 0.658 0.475 Spencer et al [13]
Major exacerbation (all ages) 0.519 0.447 0.408 Spencer et al [13]
Direct costs(2011 Can$)
g
Economic Burden of COPD
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predisposition
Some studies suggest that repeated medical advice of physicians
and educating individuals on the risk of COPD or other diseases
related to cigarette smoking can significantly increase the
probability of smoking cessation [21,22]. In this context, access
to a screening test that predicts one’s risk of developing COPD in
early smokers may result in a significant benefit [23]. We modeled
the effect of a hypothetical molecular screening test that could be
utilized to assess risk of developing COPD. We assumed that this
preventive intervention would be used to screen those who just
have started smoking (incident cases).
6. Hypothetical intervention II: New pharmacogenomic
interventions to reduce progression into more severe
disease stages
Studies for detecting treatment effect directly on clinical
outcomes (mainly phase II clinical trials) need long follow-up,
which is a major limitation for developing new treatments for
COPD [24]. Detecting novel molecular biomarkers that can
function as surrogate endpoints for characterizing COPD and its
progression could advance and accelerate the drug discovery
process [6,21].
We modeled the effect of a hypothetical pharmacogenomic
intervention that could reduce (but not reverse) the rate of disease
progression. As such, all patients with mild or moderate COPD
would remain in their current stage for a longer period of time
under this scenario.
7. Hypothetical intervention III: Predictive test for
exacerbations
Unscheduled physician visits and hospitalizations for exacerba-
tions are responsible for more than 60% of direct medical costs of
COPD [20]. Prediction of exacerbations (or exacerbators) in
advance could potentially reduce the risk of exacerbations through
the use of targeted treatments. In this scenario, we assumed that a
hypothetical molecular test could accurately predict exacerbators
and therefore by using appropriate interventions we could reduce
the frequency of exacerbations.
Results
1. Base case projections
The population over the age of 40 will increase from about 17
million to about 24 million by 2035 in Canada. Importantly,
during this time period, the population over the age of 70 will
double to approximately 8 million (Appendix S1). The model also
predicts that the number of COPD patients will increase from 3.45
million in 2011 to 5.83 million in 2035 (Figure 2). Based on these
projections, the estimated annual societal cost of COPD in
Canada is $4.52B in 2011, and will reach $3.61B ($7.33B
undiscounted) per year in 2035 (Figure 3A and 3B). Over the
next 25 years, COPD will be responsible for approximately
$101.4B in societal costs ($147.5B undiscounted) and 12.9 million
QALYs lost (19.0 million undiscounted) (Figures 4 A and B).
We also considered the proportion of COPD cases in the total
population over 40 years as an indicator of change in the burden
of COPD over the next 25 years in Canada. Our simulation
showed that the prevalence of mild COPD will increase from
12.7% to 18.5% in men and from 10.0% to 14.1% in women over
the next 25 years, while the prevalence of moderate COPD will
decrease from 9% to 6.8% in men and from 5.7% to 5.0% in
women and that for severe COPD will increase from 1% to 2.2%
in men and remain unchanged at 1.9% in women over the course
of analysis (Appendix S1).
The results of one way sensitivity analyses indicate that the total
cost of COPD over next 25 years is most sensitive to the changes in
the rates of exacerbation, followed by growth in the population,
the relative risk of COPD in previous smokers, and rates of COPD
progression in this order. Changes in the rate of spirometry testing
Table 1. Cont.
No COPD Mild Moderate Severe Reference
Maintenance 144 430 628 Spencer et al [13]
Per minor exacerbation episode 161 161 161 Spencer et al [13]
Per major exacerbation episode 6,501 6,501 6,501 Spencer et al [13]
Total direct cost per patient 572 1167 1796 Estimated, Appendix S2
Indirect costs (2011 Can$)
Maintenance 36 215 524 Estimated using Chapman et
al, Spencer et al [13,20],
Appendix S2
Minor exacerbation episode 40 80 134
Major exacerbation episode 1625 3250 5417
Total indirect cost per patient 143 583 1497 Estimated
h, Appendix S2
arates were calculated based on relative risk of mortality per smoking status [25], 2002 Canadian life tables, and 2010 mortality estimates, Statistics Canada (See
Appendix S2).
bwere estimated based on the symptom rates among smokers, previous smokers, and never smokers reported by Mannino et al [36] for men and women and also
proportion of patients without COPD reported by Buist et al [9].
cEstimated based on the reported rates for men and women in Buist et al [9] (See Appendix S2).
dEstimated based on COPD specific mortality rate of 30.4 per 10,000 (Camp et al [12]) and probabilities of major exacerbations.
eEstimated based on progression rates in Hoogendoorn et al [31] (See Appendix S2).
fthese weights are EQ-5D Scores.
gCosts in in Mannino et al [36] were multiplied by 1.155 to reflect the changes in Canadian Consumer Price Index (CPI) between 2002 and 2011.
hEstimated based on proportion of major/minor exacerbations used in Spencer et al [13].
doi:10.1371/journal.pone.0046746.t001
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only a small effect on the total costs (Figure 5).
2. Cost-effectiveness of interventions
The interventions in this study are in discovery phase and
therefore, no precise information about the intervention mecha-
nisms or their costs are currently available. In this analysis, we set
the cost for all three interventions at zero to facilitate cross-
comparisons. As such, the estimated costs and QALYs represent
the overall potential impact of these interventions on the burden of
COPD without considering the cost of the interventions. The
impact of all three interventions on total societal costs and QALYs
is shown in Table 2. The total societal costs, which were
Can$101.41 B in 2035 in the base case scenario, decreased to
$101.20B, $100.23B, and $94.27 B with interventions I, II, and III,
respectively, with each imparting 10% effect sizes. In the base case
scenario, the total QALYs lost due to COPD were 12.93 million in
2035, which was reduced to 12.90, 12.60, 12.21 million with
interventions I, II, and III, respectively, with each having 10%
effect size (Table 2). Despite a large reduction in the number of
smokers in Intervention I, the overall number of COPD cases
declined only modestly (Table 2). We observed a large decline in
the number of smokers with COPD as a result of intervention I.
However, the number of previous smokers or never smokers with
COPD increased over time.
We calculated the monetary benefit of each intervention by
converting QALYs into equivalent monetary benefit using a
willingness to pay 50,000$ per QALY gained threshold and then
adding cost savings associated with intervention. Comparison of
estimated monetary benefits shows that intervention III has a very
high potential for achieving benefits (Figure 6).
Because asthma is a risk factor for COPD and because the rates
of asthma in children and adults are increasing in the Western
World, we determined the impact of asthma on the costs and
QALYs. However, over the next 25 years, the increased rates of
asthma will have minimal impact on the costs or QALYs related to
COPD, largely because of the significant lag time between asthma
onset (which can be in childhood) to COPD diagnosis, which
occurs in 50’s and beyond and the uncertainty in the rate of
progression of COPD in ‘‘asthmatics’’ over time (see Appendix S3)
Discussion
Our findings confirm the enormous financial burden that
COPD will pose over the next 25 years. The best strategy to
reduce the growing financial and patient burden of COPD is to
reduce exacerbations. Smoking cessation, while it is the corner-
stone of COPD prevention, has only a modest effect in reducing
COPD costs over the next 25 years in Western countries such as
Canada. This is due to three important factors in COPD
pathogenesis. First, there is considerable lag time between
exposure and the onset of COPD. Although smoking rates have
fallen considerably over the past decade, many ex-smokers will
develop clinically relevant COPD with aging. Second, indepen-
dent of smoking, the rates of COPD will increase with the
increasing average age of the population [9]. Third, there is
growing evidence that COPD may continue to progress despite
smoking cessation [25]. Similarly, interventions (even very effective
ones) that reduce the rate of decline in FEV1 will have a modest
effect in reducing the economic and human burden of COPD over
the next 25 years. This is because clinically relevant outcomes such
as symptoms, hospitalizations or mortality correlate poorly with
FEV1. Indeed, there are many patients with poor FEV1 who
remain active and free of exacerbations, while there are others
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and experience frequent exacerbations [14].
In our model, the most effective strategy was to target
exacerbations. Exacerbations are expensive to treat and are
associated with considerable morbidity and mortality. The current
interventions for COPD reduce exacerbations by 20 to 30%.
However, with improved understanding of the disease, in the near
future, we may have therapies and diagnostic tests (to facilitate
more ‘‘personalized care’’) that may reduce exacerbations even
further [26,27]. If so, these interventions may have a large impact
on the financial and human burden of COPD in the Western
World.
To our best knowledge, this is the first dynamic population
model for COPD in Canada. This model has compared the
impact of population-based interventions that target different
approaches to COPD management including primary (avoiding
the development of disease), secondary (early disease detection),
and tertiary (reducing the negative impact of an already
established disease) prevention. The only other dynamic popula-
tion model was developed by Hoogendoorn et al [28–30], which
estimated the financial burden of COPD in the Dutch population
between 2000 and 2025. They projected the incidence, preva-
lence, progression and costs of COPD in that period. To illustrate
the applications of this model for effecting public health policy,
Hoogendoorn et al compared the incremental cost and incremen-
tal QALYs of adding bupropion to counseling by general
practitioners for smoking cessation. In a recent study using the
same model [31], they also compared the cost effectiveness of
three interventions (one pharmacologic, one on smoking cessation,
and one on pulmonary rehabilitation interventions) on the costs of
COPD over a 10 year time horizon.
While the current analysis relied on Canadian data and
parameters, this selection was done for illustrative purposes and
also because of the availability of robust COPD-related cost and
epidemiological data. We believe that the overall conclusions are
widely generalizable and would expect similar results in other
jurisdictions with similar population demographics such as the US.
In the US approximately 120,000 people die annually from
COPD [20] and the total economic cost of COPD was estimated
at $42.6 billion (USD) annually with more than 60% of these costs
attributed to hospitalizations, which are largely driven by
exacerbations [21].
There were some limitations to our study. There may be
unpredicted changes in the future in various parameters that were
Figure 2. The projected increase in the prevalence of COPD in Canada in men (A) and women (B) across disease severities.
doi:10.1371/journal.pone.0046746.g002
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Age was divided into only four categories. Having smaller age
groups could potentially increase the accuracy of the model.
However, this approach is limited by the availability of data. For
example, to generate accurate and robust cost data, accurate
information on COPD, smoking and mortality rates for each age
group is needed (Appendix S2). However, such data may not be
available for small age ranges. Furthermore, we did not separate
out GOLD class III from class IV disease because of the relatively
small proportion of GOLD class IV patients in Canada
(comprising ,0.2% of adults 40 years of age or older; and
,15% of combined class III/IV group), which made it difficult to
estimate accurate cost data for this group of patients. Additionally,
for parsimony, we assumed in our model that all UD and FN
COPD cases had mild disease. We did this because there is a
paucity of data on the costs generated and QALYs lost over time
for this group of patients. While this is an over-simplification of the
real world setting in which undiagnosed COPD patients can be
found in all disease severity classes, our approach yielded a
conservative estimate of the total costs of COPD and likely
Figure 3. The projected changes in the costs related to COPD in Canada in men (A) and women (B) at various discount rates.
doi:10.1371/journal.pone.0046746.g003
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Canada. Importantly, however, this approach does not materially
affect the relative impact of the three hypothetical interventions on
future costs of COPD in Canada. The use of probabilistic
sensitivity analysis for dynamic models, unlike static models, entails
additional complexities. For example, correlation between value of
variables between different time points may lead to bifurcation
[32,33]. As such, similar to previous studies based on dynamic
models [29,30], we conducted extensive univariate sensitivity
analyses to test the validity of the model and robustness of the
results. However, we acknowledge that further work is warranted
in this area. Finally, some studies suggested that incidence of
asthma in early life has increased in recent years. The
epidemiological link between asthma in early life years and
COPD later in life has been evaluated by several studies and this
relationship is indeed causal COPD rates will increase in future
Figure 4. The projected changes in quality adjusted life years lost related to COPD in Canada in men (A) and women (B).
doi:10.1371/journal.pone.0046746.g004
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effect of a future increase in COPD due to asthma. Our analysis
suggests that asthma-related increases in COPD costs will be
relatively small over the next 25 years. A larger financial impact of
asthma-related COPD will occur several decades later, owing to
the lag time between childhood and even adult-onset asthma
(occurring in 20’s and 30’s) and the onset of COPD, which
generally occurs beyond age 50.
In conclusion, our results suggest that any intervention that can
successfully reduce the number of exacerbations has an immediate
and substantial impact on morbidity and costs of COPD and
should be considered in conjunction with the ongoing efforts to
reduce smoking rates.
Figure 5. The results of one-way sensitivity analyses on the total cost related to COPD in Canada over the next 25 years.
doi:10.1371/journal.pone.0046746.g005
Figure 6. The estimated monetary benefit of each hypothetical intervention assuming different scenarios for effectiveness of these
interventions in reducing smoking rates (intervention I), progression of disease (intervention II), and exacerbation rates
(intervention II).
doi:10.1371/journal.pone.0046746.g006
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